Vir Biotechnology, Inc. (VIR)
↓ Download CSV- Sector Manufacturing
- Incorporated DE
- Fiscal year ends Dec 31
In fiscal 2025, Vir Biotechnology, Inc. reported revenue of $68.56M, down 7.6% from the prior year. The company ran a net loss, with a net margin of -638.9%. It held $1.00B in total assets against $237.55M in total liabilities.
Key ratios (FY2025)
-699.2%
Operating margin
-638.9%
Net margin
-57.2%
Return on equity
-7.6%
Revenue growth (YoY)
| Metric (FY) | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | $68.56M | $74.20M | $86.18M | $1.62B | $1.10B | $76.37M | $8.09M | $10.67M | $2.71M |
| Cost of Revenue | $26.0K | $845.0K | $2.77M | $146.32M | $65.86M | $0 | $0 | — | — |
| Operating Income | -$479.33M | -$587.16M | -$684.30M | $833.07M | $420.75M | -$296.98M | -$177.98M | -$118.69M | -$81.50M |
| Net Income | -$437.99M | -$521.96M | -$615.06M | $515.84M | $528.58M | -$298.67M | -$174.68M | -$115.88M | -$69.85M |
| EPS (Diluted) | $-3.16 | $-3.83 | $-4.59 | $3.83 | $3.96 | $-2.51 | $-5.76 | — | — |
| Total Assets | $1.00B | $1.40B | $1.92B | $2.80B | $1.95B | $918.76M | $512.07M | $191.60M | — |
| Total Liabilities | $237.55M | $248.43M | $328.82M | $724.12M | $522.42M | $201.91M | $88.13M | $61.64M | — |
| Shareholders' Equity | $765.28M | $1.15B | $1.59B | $2.08B | $1.43B | $716.85M | — | — | — |
| Cash & Equivalents | $232.19M | $222.95M | $241.58M | $848.63M | $347.81M | $436.57M | $109.33M | $47.60M | $187.92M |
| Operating Cash Flow | -$391.78M | -$446.35M | -$778.78M | $1.66B | -$47.59M | -$190.94M | -$129.63M | -$94.10M | -$66.38M |
| Capital Expenditures | $4.83M | $7.30M | $21.57M | $68.01M | $21.82M | $6.55M | $8.94M | $8.19M | $2.74M |
| Shares Outstanding | 139.47M | 136.96M | 134.78M | 133.24M | 131.16M | 127.42M | 107.65M | 8.86M | — |